Midterm Follow-Up of the St. Jude Medical® Heart Valve
From November 1918 to September 1984, 200 ST. JUDE MEDICAL® valves were implanted in 177 patients (102 AVR, 55 MVR, 20 MuVR).* The use of this low profile prosthesis is particularly appropriate in special anatomical conditions, e.g., when the aortic anulus is larger than the ascending aorta or in a small ventricular cavity. The hospital mortality was 9.8%. The 153 operative survivors were followed over a period of 3 months to 6 years (408.8 patient-years). Actuarial analysis of late results indicates an expected survival rate at 6 years of 83.1% for the whole group (AVR 81.6%, MVR 91.5%, MuVR 11.5%). Freedom from thromboembolism was 94.5% (AVR 91.3%, MVR 91.4%, MuVR 85.1%). Two patients underwent reoperation (1 endocarditis, 1 paravalvular leak). The actuarial rate of freedom from all complications was 90.1%. Postoperatively, 94% of patients were in New York Heart Association (NYHA) Class I or II. In conclusion, this midterm follow-up at 6 years shows very satisfactory results in terms of thromboembolism and survival.
KeywordsValve Replacement Aortic Valve Replacement Mitral Valve Replacement Actuarial Survival Rate Paravalvular Leak
aortic valve replacement
mitral valve replacement
multiple valve replacement
Unable to display preview. Download preview PDF.